Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
Register for PAABs ARO Q&A Session - May 18th
-
@Manufacturer @Agency
If you have questions about the launch and implementation of ARO or the submission guidelines, this session is for you.Registration is now live here for the Q&A session.
Prior to the session please ensure you are familiar with this list of resources. This session will not be didactic and will be led by participants questions.
-
There's still time to sign up and join over 150 people registered for the interactive Q&A session on the Accelerated Review Options (ARO) pathway and the new submission guidance documents.
Registration link can be found in the post above. Hope to see you there.
